Take Homes in Lung Cancer

Take Homes in Lung Cancer

Source:

Healio Interview




Disclosures: Luo reports receiving honoraria from Physicians’ Education Resource and Targeted Oncology; receiving research support to her institution from Erasca; and receiving personal fees from Blueprint Medicines, Daiichi Sankyo and Erasca.
June 23, 2022
1 min watch
Save

VIDEO: Focus on KRAS-driven lung cancer at ASCO

Source:

Healio Interview




Disclosures: Luo reports receiving honoraria from Physicians’ Education Resource and Targeted Oncology; receiving research support to her institution from Erasca; and receiving personal fees from Blueprint Medicines, Daiichi Sankyo and Erasca.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Jia Luo, MD, spoke with Healio about an educational session she chaired at ASCO Annual Meeting.

“The main take home of this talk is that we want to emphasize that KRAS-driven lung cancer is a very important topic — it’s the most common kind of oncogene-driven non-small cell lung cancer in the United States, affecting over 50,000 individuals per year alone,” Luo, thoracic medical oncologist and cancer researcher with Dana-Farber and Harvard Medical School, said.

Reference:

  • Luo J. Overcoming KRAS-Mutant Lung Cancer. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.